Viking Therapeutics' stock recently tanked after reporting clinical trial results for an oral anti-obesity candidate. The ...

We recently published 10 Stocks Hammered Harder Than Wall Street. Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of Tuesday’s ...

Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra bullish on VKTX stock.

In the second quarter, attributable net income increased by 45 percent to 1.5 billion yuan from 1.067 billion yuan in the ...

Shares of Viking Therapeutics VKTX plunged 42% yesterday after it reported top-line data from the phase II VENTURE-Oral ...

After Viking Therapeutics (VKTX) yesterday announced 13-week Phase 2 data for VK2735, an oral GIP/GLP-1-based candidate for obesity, Mizuho notes ...

The oral formulation led to up to 12.2% weight loss over three months, a weaker outcome versus late-stage treatments from Eli ...

B. Riley views the selloff in shares of Viking Therapeutics (VKTX) following VK2735 oral weight loss data as overdone. The pullback indicates the ...

Nasdaq futures dipped a further 0.4% after investors sold AI tech stocks yesterday, leading to a near-1.5% daily decline, though the index is still up 40% since April's low. Palantir ( PLTR -9.39%) ...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Spotify.